Juno Therapeutics Company Profile (NASDAQ:JUNO)

About Juno Therapeutics (NASDAQ:JUNO)

Juno Therapeutics logoJuno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:JUNO
  • CUSIP: N/A
  • Web: www.junotherapeutics.com
Capitalization:
  • Market Cap: $2.43 billion
  • Outstanding Shares: 104,145,000
Average Prices:
  • 50 Day Moving Avg: $24.42
  • 200 Day Moving Avg: $22.58
  • 52 Week Range: $17.52 - $49.72
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.24
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $88.91 million
  • Price / Sales: 27.29
  • Book Value: $9.76 per share
  • Price / Book: 2.39
Profitability:
  • EBIDTA: ($253,600,000.00)
  • Net Margins: -445.86%
  • Return on Equity: -22.10%
  • Return on Assets: -17.49%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 6.35%
  • Quick Ratio: 6.35%
Misc:
  • Average Volume: 1.61 million shs.
  • Beta: 2.27
  • Short Ratio: 8.12
 

Frequently Asked Questions for Juno Therapeutics (NASDAQ:JUNO)

What is Juno Therapeutics' stock symbol?

Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO."

How were Juno Therapeutics' earnings last quarter?

Juno Therapeutics Inc (NASDAQ:JUNO) posted its earnings results on Thursday, May, 4th. The company reported ($0.71) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by $0.01. The business had revenue of $19.30 million for the quarter, compared to analysts' expectations of $16 million. Juno Therapeutics had a negative net margin of 445.86% and a negative return on equity of 22.10%. The company's revenue for the quarter was up 96.9% on a year-over-year basis. During the same period last year, the business posted ($0.78) EPS. View Juno Therapeutics' Earnings History.

Where is Juno Therapeutics' stock going? Where will Juno Therapeutics' stock price be in 2017?

14 brokerages have issued twelve-month price targets for Juno Therapeutics' stock. Their forecasts range from $23.00 to $52.00. On average, they anticipate Juno Therapeutics' share price to reach $33.77 in the next year. View Analyst Ratings for Juno Therapeutics.

What are analysts saying about Juno Therapeutics stock?

Here are some recent quotes from research analysts about Juno Therapeutics stock:

  • 1. According to Zacks Investment Research, "Juno remains on track with its pipeline candidates and continues to pursue acquisitions and licensing agreements. Moreover, the company’s litigation settlement agreement Novartis is a huge positive. However, the company recently suffered a huge setback as it discontinued the development of its cancer drug JCAR015 due to the toxicity witnessed in a phase II ROCKET study. Moreover, increased competition in the immunotherapy space is a matter of concern for the company as several companies are looking to bring these treatments to the market. Juno’s shares outperformed the Medical-Biomed/Genetics industry significantly so far this year. Estimates have been going up lately ahead of the company’s Q1 earnings release. The company has mixed record of earnings surprises in recent quarters." (5/2/2017)
  • 2. Cowen and Company analysts commented, "We believe initial data from the Phase I TRANSCEND study indicate that JCAR017 is." (3/30/2017)
  • 3. Wedbush analysts commented, "We see significant value in JUNO's leading array of engineered T-cell technologies that we believe could allow for a differentiated strategy in B-cell malignancies, despite being behind the competition in the race to market. However, competition from other CAR-T products is likely to limit shareholder upside in the near term." (2/1/2017)
  • 4. Leerink Swann analysts commented, "We’re using a 12% discount rate which we think is appropriate as we use probability-weighted sales estimates for the products and believe the CELG (MP) collaboration, equity investment and ex-US opt-in to CD19 programs lower the risk profile relative to Juno’s peers. We assume the CAR-T market will be split among up to 5 competitors long-term, depending on the indication, including JUNO, KITE, NVS, CLLS, BLUE and others, pending further validation of respective products. Based on the complexity of the technology and manufacturing and the lack of regulatory path for generic versions of CAR-T products as a result of patient-specific manufacturing, we believe that CAR-T product sales are sustainable even after the loss of patent exclusivity." (11/28/2016)

Who are some of Juno Therapeutics' key competitors?

When did Juno Therapeutics IPO?

(JUNO) raised $153 million in an IPO on Friday, December 19th 2014. The company issued 9,300,000 shares at $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Leerink Partners was co-manager.

Who owns Juno Therapeutics stock?

Juno Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (10.83%), CELGENE SWITZERLAND LLC (9.70%), Vanguard Group Inc. (5.95%), BlackRock Inc. (4.05%), State Street Corp (2.89%) and BB Biotech AG (2.11%). Company insiders that own Juno Therapeutics stock include Anthony B Evnin, Bernard J Cassidy, Douglas K Bratton, Hans Edgar Bishop, Hyam Levitsky, Jay T Flatley, Richard Klausner, Robert Azelby and Steve Harr. View Institutional Ownership Trends for Juno Therapeutics.

Who sold Juno Therapeutics stock? Who is selling Juno Therapeutics stock?

Juno Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Morgan Stanley, SG Americas Securities LLC, Mitsubishi UFJ Trust & Banking Corp, State of Wisconsin Investment Board, Bank of America Corp DE, ProShare Advisors LLC and Candriam Luxembourg S.C.A.. Company insiders that have sold Juno Therapeutics stock in the last year include Hans Edgar Bishop, Hyam Levitsky, Richard Klausner, Robert Azelby and Steve Harr. View Insider Buying and Selling for Juno Therapeutics.

Who bought Juno Therapeutics stock? Who is buying Juno Therapeutics stock?

Juno Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., First Trust Advisors LP, BB Biotech AG, Vanguard Group Inc., Broadfin Capital LLC, Peconic Partners LLC, Baillie Gifford & Co. and Credit Suisse AG. Company insiders that have bought Juno Therapeutics stock in the last two years include Anthony B Evnin and Jay T Flatley. View Insider Buying and Selling for Juno Therapeutics.

How do I buy Juno Therapeutics stock?

Shares of Juno Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Juno Therapeutics stock cost?

One share of Juno Therapeutics stock can currently be purchased for approximately $23.30.

Analyst Ratings

Consensus Ratings for Juno Therapeutics (NASDAQ:JUNO) (?)
Ratings Breakdown: 8 Hold Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $33.77 (44.93% upside)

Analysts' Ratings History for Juno Therapeutics (NASDAQ:JUNO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017FBR & CoReiterated RatingHoldMediumView Rating Details
5/15/2017WedbushReiterated RatingNeutral$24.00N/AView Rating Details
5/8/2017Morgan StanleyLower Price TargetEqual Weight$27.00 -> $26.00HighView Rating Details
4/4/2017Citigroup IncLower Price TargetBuy$34.00 -> $30.00LowView Rating Details
3/30/2017Cowen and CompanyReiterated RatingBuy$41.00 -> $36.00LowView Rating Details
3/3/2017JPMorgan Chase & Co.Reiterated RatingNeutral$34.00 -> $31.00N/AView Rating Details
3/2/2017Maxim GroupSet Price TargetBuy$34.00N/AView Rating Details
2/22/2017Wells Fargo & CoInitiated CoverageOutperform -> OutperformN/AView Rating Details
12/6/2016Raymond James Financial, Inc.Reiterated RatingOutperform -> Market PerformN/AView Rating Details
11/28/2016Leerink SwannReiterated RatingOutperform$45.00 -> $34.00N/AView Rating Details
11/25/2016SunTrust Banks, Inc.DowngradeBuy -> Hold$48.00 -> $25.00N/AView Rating Details
11/23/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
8/25/2016Standpoint ResearchInitiated CoverageBuy$47.00N/AView Rating Details
7/6/2016Barclays PLCInitiated CoverageEqual Weight$48.00N/AView Rating Details
2/27/2016Deutsche Bank AGInitiated CoverageBuyN/AView Rating Details
2/22/2016Goldman Sachs Group IncLower Price Target$50.00 -> $41.00N/AView Rating Details
2/17/2016GuggenheimUpgradeNeutral -> BuyN/AView Rating Details
7/22/2015Northland SecuritiesInitiated CoverageOutperform$64.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Juno Therapeutics (NASDAQ:JUNO)
Earnings by Quarter for Juno Therapeutics (NASDAQ:JUNO)
Earnings History by Quarter for Juno Therapeutics (NASDAQ:JUNO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.70)($0.71)$16.00 million$19.30 millionViewListenView Earnings Details
3/1/2017Q416($0.61)($0.65)$14.57 million$21.15 millionViewListenView Earnings Details
11/9/2016Q316($0.52)($0.57)$10.98 million$20.80 millionViewListenView Earnings Details
8/4/2016Q216($0.41)($0.64)$14.26 million$27.60 millionViewListenView Earnings Details
5/9/2016Q116($0.52)($0.78)$4.83 million$9.80 millionViewListenView Earnings Details
2/29/2016Q415($0.54)($0.53)$4.79 million$4.15 millionViewListenView Earnings Details
11/10/2015Q315($0.41)($0.53)$6.41 million$1.60 millionViewListenView Earnings Details
8/12/2015Q215($0.37)($0.35)$2.03 million$12.50 millionViewListenView Earnings Details
5/11/2015Q115($0.35)($0.30)ViewListenView Earnings Details
3/18/2015Q414($0.33)($1.73)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Juno Therapeutics (NASDAQ:JUNO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.70)($0.70)($0.70)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Juno Therapeutics (NASDAQ:JUNO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Juno Therapeutics (NASDAQ:JUNO)
Insider Ownership Percentage: 15.26%
Institutional Ownership Percentage: 61.80%
Insider Trades by Quarter for Juno Therapeutics (NASDAQ:JUNO)
Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)
Insider Trades by Quarter for Juno Therapeutics (NASDAQ:JUNO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/26/2017Jay T FlatleyDirectorBuy20,000$24.76$495,200.00View SEC Filing  
3/10/2017Anthony B EvninDirectorBuy8,000$22.11$176,880.00View SEC Filing  
11/10/2016Robert AzelbyEVPSell12,921$24.14$311,912.94View SEC Filing  
9/27/2016Hans Edgar BishopCEOSell44,000$33.00$1,452,000.00View SEC Filing  
9/21/2016Hans Edgar BishopCEOSell84,035$30.28$2,544,579.80View SEC Filing  
9/8/2016Hans Edgar BishopCEOSell23,042$30.06$692,642.52View SEC Filing  
6/24/2016Richard KlausnerDirectorSell12,000$40.71$488,520.00View SEC Filing  
6/17/2016Hyam LevitskyEVPSell12,418$42.77$531,117.86View SEC Filing  
6/10/2016Steve HarrCFOSell30,000$43.32$1,299,600.00View SEC Filing  
6/9/2016Hans Edgar BishopCEOSell90,750$46.42$4,212,615.00View SEC Filing  
5/19/2016Bernard J CassidyGeneral CounselSell3,116$39.03$121,617.48View SEC Filing  
5/18/2016Richard KlausnerDirectorSell12,000$40.00$480,000.00View SEC Filing  
4/19/2016Bernard J CassidyGeneral CounselSell3,200$43.12$137,984.00View SEC Filing  
4/15/2016Richard KlausnerDirectorSell12,000$42.90$514,800.00View SEC Filing  
3/28/2016Anthony B EvninDirectorBuy8,000$36.58$292,640.00View SEC Filing  
3/22/2016Richard KlausnerDirectorSell12,000$40.00$480,000.00View SEC Filing  
3/18/2016Bernard J CassidyGeneral CounselSell3,200$38.18$122,176.00View SEC Filing  
3/4/2016Steve HarrInsiderSell5,000$45.00$225,000.00View SEC Filing  
3/2/2016Richard KlausnerDirectorSell24,000$40.42$970,080.00View SEC Filing  
3/1/2016Douglas K BrattonMajor ShareholderSell8,600,000$39.00$335,400,000.00View SEC Filing  
3/1/2016Steve HarrInsiderSell30,000$37.58$1,127,400.00View SEC Filing  
2/19/2016Bernard J. CassidyGeneral CounselSell3,200$34.50$110,400.00View SEC Filing  
1/19/2016Bernard J. CassidyGeneral CounselSell3,200$33.55$107,360.00View SEC Filing  
12/18/2015Bernard J. CassidyGeneral CounselSell3,200$45.39$145,248.00View SEC Filing  
12/10/2015Steve HarrinsiderSell35,000$46.43$1,625,050.00View SEC Filing  
11/19/2015Bernard J. CassidyGeneral CounselSell3,200$52.97$169,504.00View SEC Filing  
11/13/2015Richard KlausnerDirectorSell12,000$49.51$594,120.00View SEC Filing  
10/19/2015Bernard J. CassidyGeneral CounselSell3,200$49.85$159,520.00View SEC Filing  
10/15/2015Richard KlausnerDirectorSell8,000$50.00$400,000.00View SEC Filing  
10/12/2015Richard KlausnerDirectorSell16,000$50.00$800,000.00View SEC Filing  
9/18/2015Bernard J. CassidyGeneral CounselSell11,850$42.50$503,625.00View SEC Filing  
8/19/2015Bernard J. CassidyGeneral CounselSell11,850$40.15$475,777.50View SEC Filing  
7/17/2015Bernard J CassidyGeneral CounselSell11,850$50.55$599,017.50View SEC Filing  
7/15/2015Richard KlausnerDirectorSell8,000$53.34$426,720.00View SEC Filing  
7/2/2015Douglas K BrattonMajor ShareholderSell40,000$54.75$2,190,000.00View SEC Filing  
6/26/2015Anthony B EvninDirectorSell583,333$48.11$28,064,150.63View SEC Filing  
6/24/2015Bernard J CassidyGeneral CounselSell11,850$51.34$608,379.00View SEC Filing  
6/24/2015Douglas K BrattonMajor ShareholderSell270,000$51.13$13,805,100.00View SEC Filing  
6/23/2015Richard KlausnerDirectorSell8,000$52.29$418,320.00View SEC Filing  
6/18/2015Anthony B EvninDirectorSell583,333$52.88$30,846,649.04View SEC Filing  
12/23/2014Douglas K BrattonMajor ShareholderBuy625,000$24.00$15,000,000.00View SEC Filing  
12/23/2014Hal BarronDirectorBuy100,000$24.00$2,400,000.00View SEC Filing  
12/19/2014Douglas K BrattonMajor ShareholderBuy625,000$25.00$15,625,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Juno Therapeutics (NASDAQ:JUNO)
Latest Headlines for Juno Therapeutics (NASDAQ:JUNO)
Source:
DateHeadline
americanbankingnews.com logoZacks: Brokerages Anticipate Juno Therapeutics Inc (JUNO) Will Announce Quarterly Sales of $17.18 Million
www.americanbankingnews.com - May 28 at 10:22 AM
fool.com logoI Still Can't Believe Juno Therapeutics Spent $46.4 Million on This Failed Drug - Motley Fool
www.fool.com - May 27 at 4:57 AM
americanbankingnews.com logoJay T. Flatley Buys 20,000 Shares of Juno Therapeutics Inc (JUNO) Stock
www.americanbankingnews.com - May 26 at 10:24 PM
americanbankingnews.com logoZacks: Analysts Anticipate Juno Therapeutics Inc (JUNO) to Announce -$0.78 EPS
www.americanbankingnews.com - May 26 at 8:10 AM
americanbankingnews.com logoJuno Therapeutics Inc (JUNO) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 26 at 7:59 AM
seekingalpha.com logo3 Companies With Three Different Approaches To Immuno-Oncology
seekingalpha.com - May 24 at 6:05 PM
businesswire.com logoJuno Therapeutics Appoints Jay Flatley to Board of Directors - Business Wire (press release)
www.businesswire.com - May 24 at 11:19 AM
americanbankingnews.com logoVetr Inc. Upgrades Juno Therapeutics Inc (JUNO) to Buy
www.americanbankingnews.com - May 23 at 11:48 PM
finance.yahoo.com logoVetr Upgrades Juno To Buy Amid Volatile May
finance.yahoo.com - May 23 at 11:00 AM
finance.yahoo.com logoJuno Therapeutics Appoints Jay Flatley to Board of Directors
finance.yahoo.com - May 23 at 11:00 AM
americanbankingnews.com logoJuno Therapeutics Inc (JUNO) Stock Rating Reaffirmed by FBR & Co
www.americanbankingnews.com - May 19 at 7:16 PM
nasdaq.com logoJUNO Makes Notable Cross Below Critical Moving Average
www.nasdaq.com - May 17 at 11:06 PM
bizjournals.com logoSneak peek: Tour Juno Therapeutics' copper-plated South Lake Union headquarters (Photos)
www.bizjournals.com - May 17 at 11:06 PM
businesswire.com logoJuno Therapeutics to Present Key Clinical Data Updates on JCAR017 and JCAR014 at the 2017 American Society of ... - Business Wire (press release)
www.businesswire.com - May 17 at 6:05 PM
seekingalpha.com logoFate Therapeutics, Inc. (FATE)
seekingalpha.com - May 15 at 5:34 PM
finance.yahoo.com logoBlog Coverage: Aevi Genomics Announces Phase 2 Clinical Trial and Reports Q1 2017 Results
finance.yahoo.com - May 11 at 3:37 PM
businesswire.com logoJuno Therapeutics to Present at the Bank of America Merrill Lynch 2017 Health Care Conference - Business Wire (press release)
www.businesswire.com - May 11 at 7:49 AM
finance.yahoo.com logoVetr Urges Buy On Juno After Earnings
finance.yahoo.com - May 9 at 12:08 PM
finance.yahoo.com logoJuno Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : JUNO-US : May 9, 2017
finance.yahoo.com - May 9 at 12:08 PM
americanbankingnews.com logoJuno Therapeutics Inc (JUNO) Earns "Equal Weight" Rating from Morgan Stanley
www.americanbankingnews.com - May 8 at 8:30 PM
finance.yahoo.com logoKite Pharma Discloses CAR-T Patient Death, Rattling Investors
finance.yahoo.com - May 8 at 5:45 PM
finance.yahoo.com logoHere's Why Kite Pharma (KITE) Stock Is Plummeting Today
finance.yahoo.com - May 8 at 5:45 PM
finance.yahoo.com logoHere's What's Dragging Kite Pharma Inc. Down Today
finance.yahoo.com - May 8 at 5:45 PM
americanbankingnews.com logoFBR & Co Trims Juno Therapeutics Inc (JUNO) Target Price to $29.00
www.americanbankingnews.com - May 6 at 3:56 PM
fool.com logoJuno Therapeutics Q1 Revenue Improves Thanks to Celgene Collaboration - Motley Fool
www.fool.com - May 5 at 6:06 PM
americanbankingnews.com logoWedbush Reaffirms Neutral Rating for Juno Therapeutics Inc (JUNO)
www.americanbankingnews.com - May 5 at 10:30 AM
reuters.com logoBRIEF-Juno Therapeutics reports Q1 loss per share $0.79
www.reuters.com - May 5 at 4:20 AM
americanbankingnews.com logoJuno Therapeutics Inc (JUNO) Posts Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - May 4 at 11:36 PM
businesswire.com logoJuno Therapeutics Reports First Quarter 2017 Financial Results - Business Wire (press release)
www.businesswire.com - May 4 at 11:19 PM
seekingalpha.com logoJuno Therapeutics (JUNO)
seekingalpha.com - May 4 at 6:17 PM
americanbankingnews.com logoZacks: Analysts Anticipate Juno Therapeutics Inc (JUNO) Will Announce Quarterly Sales of $17.75 Million
www.americanbankingnews.com - May 4 at 11:26 AM
americanbankingnews.com logoJuno Therapeutics (JUNO) Receiving Somewhat Positive News Coverage, Report Shows
www.americanbankingnews.com - May 3 at 1:04 AM
americanbankingnews.com logoJuno Therapeutics Inc (JUNO) Expected to Post Earnings of -$0.66 Per Share
www.americanbankingnews.com - May 2 at 10:10 PM
americanbankingnews.com logoJuno Therapeutics Inc (JUNO) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 2 at 1:56 PM
nasdaq.com logoWhat's in Store for Juno Therapeutics (JUNO) in Q1 Earnings?
www.nasdaq.com - May 1 at 6:05 PM
americanbankingnews.com logoJuno Therapeutics Inc (JUNO) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - May 1 at 10:58 AM
businesswire.com logoJuno Therapeutics to Report First Quarter 2017 Financial Results on ... - Business Wire (press release)
www.businesswire.com - April 28 at 7:04 PM
finance.yahoo.com logoJuno Therapeutics to Report First Quarter 2017 Financial Results on ... - Yahoo Finance
finance.yahoo.com - April 28 at 9:39 AM
americanbankingnews.com logoJuno Therapeutics (JUNO) Given News Impact Rating of 0.19
www.americanbankingnews.com - April 28 at 12:12 AM
prnewswire.com logoInvestors: Option Trade reports for Juno Therapeutics Inc, Lumber Liquidators, Las Vegas Sands, Twitter and US Steel.
www.prnewswire.com - April 27 at 6:40 PM
benzinga.com logoFreeport-McMoRan, Juno Therapeutics, Square And European Banks: Fast Money Picks For April 26
www.benzinga.com - April 26 at 7:13 PM
americanbankingnews.com logoJuno Therapeutics (JUNO) Receiving Favorable Press Coverage, Report Finds
www.americanbankingnews.com - April 23 at 12:58 PM
finance.yahoo.com logoWill Juno Therapeutics (JUNO) Continue to Surge Higher? - Yahoo Finance
finance.yahoo.com - April 22 at 5:31 AM
americanbankingnews.com logoJuno Therapeutics (JUNO) Receiving Somewhat Favorable News Coverage, Analysis Shows
www.americanbankingnews.com - April 20 at 11:51 PM
bizjournals.com logoClub with boutique bouldering gym leases space in Juno's new South Lake Union headquarters
www.bizjournals.com - April 20 at 11:12 PM
nasdaq.com logoCommit To Purchase Juno Therapeutics At $20, Earn 15.7% Annualized Using Options
www.nasdaq.com - April 20 at 6:11 PM
streetinsider.com logoJuno Therapeutics (JUNO) Appoints Rupert Vessey to Board of Directors
www.streetinsider.com - April 19 at 11:12 AM
finance.yahoo.com logoJuno Therapeutics Appoints Rupert Vessey to Board of Directors
finance.yahoo.com - April 19 at 11:12 AM
finance.yahoo.com logoJuno Therapeutics Appoints Sunil Agarwal as President of Research and Development
finance.yahoo.com - April 17 at 10:42 AM
americanbankingnews.com logoJuno Therapeutics (JUNO) Receives News Sentiment Rating of 0.17
www.americanbankingnews.com - April 15 at 2:55 PM

Social

Chart

Juno Therapeutics (JUNO) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff